Last updated on March 2020

Safety and Efficacy of the Transfusion of UCB in Patients With an ASD Depending on the Degree of HLA Compatibility.


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Autism Spectrum Disorder | Pervasive developmental disorder | Autism Spectrum Disorder (ASD) | Autism
  • Age: Between 3 - 14 Years
  • Gender: Male or Female

Patient selection criteria (indications for this type of treatment):

  • Patient's age from 4 to 14 years;
  • Diagnosis: autistic spectrum disorder;
  • The severity of the disease on the ATEC scale of at least 16 points;
  • The presence of a compatible allogeneic sample suitable for infusion;
  • Parental consent (official guardians).

Patient exclusion criteria (contraindications for this type of treatment):

  • The patient's age under 4 years, after 14 years;
  • The presence of the following diseases in the history: heart failure at the stage of decompensation, stroke in the history of less than 1 year ago, anemia and other blood diseases;
  • Decompensation for chronic and endocrinological diseases;
  • Acute viral and bacterial infections during the acute clinical phase of the disease;
  • HIV infection, hepatitis B and C;
  • Cancer, chemotherapy, and history of cancer;
  • Tuberculosis;
  • Severe form of intellectual disability as a concomitant disease (diagnosis can be ignored, according to the decision of the Medical Committee of the Center);
  • Fragile X chromosome syndrome;
  • Epileptic seizures with or without medication in the last 6 months before inclusion in the protocol.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.